MedTrace Logo

Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Rhinovirus Induced Common Cold

NCT02522949 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-08-23

Study results available
· View outcomes & findings →

Summary

This study evaluates the performance of ColdZyme® mouth spray on prevention and alleviation of induced rhinovirus upper respiratory tract infection in healthy volunteers. Half of participants will receive ColdZyme® mouth spray while the other half will receive placebo.

Conditions

  • Common Cold

Interventions

DEVICE

ColdZyme® mouth spray

DEVICE

Placebo

Sponsors & Collaborators

  • Enzymatica AB

    lead INDUSTRY

Principal Investigators

  • Cecilia Ahlström Emanuelsson, MD · Otorhinolaryngology, Skåne University Hospital, Lund.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-06-30
Completion
2013-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02522949 on ClinicalTrials.gov